Overview

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Status:
Active, not recruiting

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: - Trastuzumab emtansine (also called T-DM1) - Pertuzumab

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Genentech, Inc.

Treatments:

Ado-trastuzumab emtansine
Pertuzumab